Compare Regeneron Pharmaceuticals Inc (REGN) vs ABRDN Physical Gold Shares ETF (SGOL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $652.76 (market cap $70.79B), while ABRDN Physical Gold Shares ETF trades at $39.1. The key difference: Regeneron Pharmaceuticals Inc pays a 0.56% dividend while ABRDN Physical Gold Shares ETF pays none. Which is the better fit depends on your goals.
| REGN | SGOL | |
|---|---|---|
Market Cap | $70.79B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $812.27 | $51.41 |
52-Week Low | $545.46 | $31.18 |
Enterprise Value | $64.74B | — |
Dividend Yield | 0.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $675.19, down 0.22% on the day, with a bullish technical signal from moving averages. The company shows strong fundamentals with a P/E of 16.41, net income margin of 29.65%, and consistent earnings beats in recent quarters. However, sentiment is clouded by a securities class action lawsuit related to a Phase 3 clinical trial failure disclosed in July 2026.
The outlook remains positive based on analyst consensus with a $764.50 price target and 69% buy ratings, but near-term volatility is likely due to legal overhangs. Investment opportunity lies in robust profitability and growth prospects, while key risks include litigation outcomes and clinical trial setbacks.
SGOL is trading at $38.16, down 0.16% with bearish technical signals dominating. The stock shows 16 sell signals versus only 1 buy signal across technical indicators, with moving averages indicating strong bearish momentum. Recent gold market volatility and interest rate expectations are creating headwinds for gold-related assets. The stock lacks available fundamental data for traditional valuation metrics.
The outlook remains cautious given the bearish technical setup and gold market uncertainty. Investment opportunities exist for contrarian investors betting on gold's safe-haven appeal amid geopolitical tensions. Key risks include continued interest rate pressure, gold price volatility, and the stock's technical weakness potentially extending further.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About ABRDN Physical Gold Shares ETF
SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →
